Key facts
- It has raised $17.9M; the latest was Later Stage VC ($3.9M) in Jun 2024.
- Notable investors include European Commission, European Union, NLC Health Ventures, Ellerston Capital, Canaccord Genuity Wealth Management — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for NicoLab
- ·The full record, as it builds
Funding rounds
No funding rounds for NicoLab are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NicoLab
Developer of an artificial intelligence-powered clinical decision support system designed to offer a complete assessment of relevant imaging biomarkers. The company's system assesses all-important biomarkers on emergency computed tomography and notifies of findings, enabling physicians to aid in the timely and accurate triaging of stroke victims.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2015
- Employees
- 58
- Website
- nicolab.com/
- Ownership
- Privately Held (backing)
NicoLab doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NicoLab shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NicoLab in its N-PORT filings yet. We sweep new filings monthly.